| Effects |
(1) 7 days (7.5 mg/kg/day in phosphate-buffered saline, delivered intravenously via tail vein) was able to clear and reduce existing plaque deposits (~30%), (2) Chronic therapy for 5 months with low doses of curcumin formulated in chow (500 ppm) led to a reduction of Aβ levels by 40% and produced a 43% decrease in Aβ deposits compared with control group, (3) The curcumin therapy with low doses reduced the astrocytic marker GFAP and decreases by 43–50% plaque burden, insoluble and soluble Aβ, (4) curcumin gavage on the prevention and therapy of AD in doses of 400, 200 and 100 mg/kg/day (suspended in 0.5% sodium carboxymethyl cellulose solution) for 3 months. Behavioural tests have shown that medium- and high-doses of curcumin treatment can improve spatial learning and memory capacity in these mice. Immunohistochemical and Western blot analyses revealed a reduction of Aβ(1-40), Aβ(1-42) and aggregation of amyloid-β in the CA1 hippocampal area, a decrease in the expression of the γ-secretase component presenilin-2 and an intensification in the expression of amyloid-β degrading enzymes, |
